Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
21 March 2023Website:
http://zurabio.comNext earnings report:
14 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 12 min agoDividend
Analysts recommendations
Institutional Ownership
ZURA Latest News
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today shared supportive data from a Phase 1 study evaluating its lead candidate, tibulizumab (ZB-106), for the treatment of Sjogren's syndrome. These data, along with preclinical data supporting further development of tibulizumab in rheumatoid arthritis (RA), were presented at the Annual European Co.
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced it will present data from its tibulizumab (ZB-106) program exploring the clinical potential of the dual-pathway antibody in Sjogren's syndrome and rheumatoid arthritis (RA) at EULAR 2024, June 12-15 in Vienna. “We are excited to present translational data from our tibulizumab (ZB-106.
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of senior management will participate in two investor conferences in June. Conference Details: Event: Jefferies Global Healthcare Conference Details: Michael Howell, Ph.D., Chief Scientific Officer and Head of Translational Medicine, will participate in one-on-one meetin.
The average price targets from Wall Street analysts suggest a potential upside of 248.8% for Zura Bio Limited (ZURA). Although the reliability of this metric is uncertain, the positive trend in earnings estimate revisions could lead to an increase in the stock's value.
Zura Bio Limited (ZURA) could see an increase in its stock price due to increasing confidence in its earnings potential, as evidenced by its upgrade to a Zacks Rank #2 (Buy).
Zura Bio's lead therapy is ZB-106. The company plans to start two phase 2 trials for the therapy.
Zura Bio (NASDAQ: ZURA ) stock is on the move Thursday following the clinical-stage biotechnology company's recent public debut. Zura Bio went public on Tuesday after completing its special purpose acquisition company (SPAC) merger with JATT Acquisition Corp. Afterward, the company's shares saw a massive spike in price during trading on Wednesday.
What type of business is Zura Bio Limited?
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
What sector is Zura Bio Limited in?
Zura Bio Limited is in the Healthcare sector
What industry is Zura Bio Limited in?
Zura Bio Limited is in the Biotechnology industry
What country is Zura Bio Limited from?
Zura Bio Limited is headquartered in United States
When did Zura Bio Limited go public?
Zura Bio Limited initial public offering (IPO) was on 21 March 2023
What is Zura Bio Limited website?
https://zurabio.com
Is Zura Bio Limited in the S&P 500?
No, Zura Bio Limited is not included in the S&P 500 index
Is Zura Bio Limited in the NASDAQ 100?
No, Zura Bio Limited is not included in the NASDAQ 100 index
Is Zura Bio Limited in the Dow Jones?
No, Zura Bio Limited is not included in the Dow Jones index
When does Zura Bio Limited report earnings?
The next expected earnings date for Zura Bio Limited is 14 August 2024